- Merck diabetes drug Sitagliptin was hit by carcinogenic impurities
- CDC relaxes and reiterates its COVID-19 guidance
- How does NOVAVAX solve the dilemma when COVID-19 vaccine sales plummeted by 90%?
- Scientists develop new antibiotic molecule that kills several superbugs
- UK: The polio vaccine booster recommended for all children aged 1 to 9 in London
- Russia has discovered a new COVID-19 “Deltacron” hybrid variant
China mRNA Vaccine: Hong Kong will purchase 7.5 million vaccines
China mRNA Vaccine: Hong Kong will purchase 7.5 million vaccines . The Hong Kong Special Administrative Region Government plans to purchase 7.5 million doses of Fosun Pharma’s mRNA COVID-19 vaccines.
On December 11, the Government of the Hong Kong Special Administrative Region announced that it had reached an agreement with Fosun Pharma (600196.SH, 02196.HK) to purchase up to 7.5 million doses jointly developed by Fosun Pharma and Germany’s BioNTech. mRNA COVID-19 nucleic acid vaccine (BNT162b2). Among them, the first batch of 1 million doses of vaccine is expected to be delivered as soon as the first quarter of next year.
On December 12, the reporter learned from Fosun Pharma that the “Fosun COVID-19 Vaccine” to be supplied in Hong Kong will be produced by Fosun Pharma’s partner in Germany, Baintech, and the two parties will cooperate in development.
On November 24th, Fosun Pharma launched Phase II clinical trials of the vaccine in China in Taizhou and Lianshui, Jiangsu Province, and actively promoted the launch of the vaccine. Recently, the development of the vaccine in overseas markets has frequently reported good news. On December 12, the COVID-19 vaccine officially obtained an emergency use authorization (EUA) from the US FDA, which is suitable for people over 16 years old. Prior to this, this vaccine has also been authorized for use by regulatory agencies in the United Kingdom, Bahrain, Canada, Saudi Arabia and Mexico.
Some analysts said that the emergency use authorization of the vaccine obtained in overseas markets is expected to speed up its authorization to use in Hong Kong, China.
Fosun Pharma previously stated that it is actively discussing and preparing the required documents for registration with the Hong Kong Department of Health and will submit the documents for approval as soon as possible.